Deutsche Bank AG Reduces Stake in Insmed, Inc. $INSM

Deutsche Bank AG cut its stake in shares of Insmed, Inc. (NASDAQ:INSM - Free Report) by 36.5% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 310,618 shares of the biopharmaceutical company's stock after selling 178,348 shares during the quarter. Deutsche Bank AG owned approximately 0.17% of Insmed worth $23,697,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of INSM. M&T Bank Corp lifted its stake in shares of Insmed by 4.7% during the 1st quarter. M&T Bank Corp now owns 3,293 shares of the biopharmaceutical company's stock worth $252,000 after purchasing an additional 147 shares during the last quarter. Snowden Capital Advisors LLC raised its stake in Insmed by 2.5% in the fourth quarter. Snowden Capital Advisors LLC now owns 6,602 shares of the biopharmaceutical company's stock valued at $456,000 after buying an additional 158 shares during the last quarter. Cullen Frost Bankers Inc. raised its stake in Insmed by 164.9% in the first quarter. Cullen Frost Bankers Inc. now owns 355 shares of the biopharmaceutical company's stock valued at $27,000 after buying an additional 221 shares during the last quarter. Nisa Investment Advisors LLC raised its stake in Insmed by 6.5% in the first quarter. Nisa Investment Advisors LLC now owns 3,761 shares of the biopharmaceutical company's stock valued at $287,000 after buying an additional 228 shares during the last quarter. Finally, Parkman Healthcare Partners LLC raised its stake in Insmed by 0.7% in the fourth quarter. Parkman Healthcare Partners LLC now owns 35,668 shares of the biopharmaceutical company's stock valued at $2,463,000 after buying an additional 235 shares during the last quarter.

Insider Transactions at Insmed

In related news, insider Orlov S. Nicole Schaeffer sold 99,172 shares of the business's stock in a transaction on Wednesday, June 11th. The stock was sold at an average price of $93.42, for a total value of $9,264,648.24. Following the sale, the insider owned 89,407 shares in the company, valued at approximately $8,352,401.94. The trade was a 52.59% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO William Lewis sold 6,830 shares of the business's stock in a transaction on Tuesday, July 15th. The shares were sold at an average price of $102.37, for a total value of $699,187.10. Following the completion of the sale, the chief executive officer owned 233,924 shares in the company, valued at $23,946,799.88. This represents a 2.84% decrease in their position. The disclosure for this sale can be found here. Insiders have sold a total of 525,716 shares of company stock worth $49,665,671 over the last quarter. 3.00% of the stock is owned by corporate insiders.

Analyst Upgrades and Downgrades

A number of equities research analysts have commented on INSM shares. HC Wainwright increased their price target on Insmed from $90.00 to $120.00 and gave the company a "buy" rating in a research note on Wednesday, June 11th. JPMorgan Chase & Co. raised their target price on Insmed from $90.00 to $111.00 and gave the stock an "overweight" rating in a report on Tuesday, July 8th. Jefferies Financial Group raised their target price on Insmed from $129.00 to $148.00 and gave the stock a "buy" rating in a report on Wednesday, August 13th. Morgan Stanley reissued an "equal weight" rating and issued a $126.00 price objective on shares of Insmed in a report on Wednesday, August 13th. Finally, Stifel Nicolaus lifted their price target on Insmed from $121.00 to $145.00 and gave the stock a "buy" rating in a research note on Thursday. One equities research analyst has rated the stock with a hold rating and fifteen have issued a buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average price target of $129.57.

Insmed Trading Up 1.5%

Shares of Insmed stock traded up $1.91 during trading hours on Monday, hitting $129.71. The company's stock had a trading volume of 1,043,692 shares, compared to its average volume of 2,822,888. Insmed, Inc. has a twelve month low of $60.40 and a twelve month high of $130.13. The firm has a fifty day moving average of $103.62 and a 200-day moving average of $83.97. The stock has a market cap of $27.42 billion, a price-to-earnings ratio of -22.71 and a beta of 0.95. The company has a debt-to-equity ratio of 0.45, a quick ratio of 6.33 and a current ratio of 6.68.

Insmed (NASDAQ:INSM - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The biopharmaceutical company reported ($1.70) EPS for the quarter, missing the consensus estimate of ($1.30) by ($0.40). Insmed had a negative net margin of 259.82% and a negative return on equity of 195.37%. The business had revenue of $107.42 million during the quarter, compared to analyst estimates of $104.06 million. During the same period last year, the company earned ($1.94) EPS. The business's revenue for the quarter was up 18.9% on a year-over-year basis. Research analysts forecast that Insmed, Inc. will post -4.56 EPS for the current year.

Insmed Company Profile

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.